Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Preliminary Q3 Revenues Up 26 Percent

NEW YORK – Qiagen on Tuesday reported a 26 percent year-over-year increase in its preliminary third quarter revenues, both at actual and constant exchange rates, driven by COVID-19 testing and improved customer demand for other products.

The company booked $481.3 million in preliminary revenues for the quarter, up from $382.7 million during the same quarter last year. In July, Qiagen had predicted Q3 sales to grow between 16 percent and 21 percent. Analysts, on average, expect revenues of $461 million.

Qiagen said the results reflect ongoing demand for its products related to COVID-19 testing as well as improved customer demand in other areas of its portfolio, compared to the second quarter of this year. However, non-COVID-19 product sales declined at a mid-single-digit rate compared to Q3 of 2019. Specifically, sales of the QuantiFeron-TB test for tuberculosis detection declined 20 percent year over year to about $53 million.

The company reported preliminary adjusted earnings per share of about $.58 for the quarter, compared to adjusted EPS of $.36 a year ago. Qiagen in July had forecast EPS of $.52 to $.58 for the third quarter, and analysts are predicting EPS of $.56.

Based on exchange rates on September 30, Qiagen expects currency movements against the US dollar to have a positive impact on Q3 results of less than a percentage point on revenues and less than $.01 on adjusted EPS.

The company is scheduled to report its full Q3 results on Nov. 4, followed by a conference call on November 5.

In morning trading on the New York Stock Exchange, Qiagen's shares were down more than 3 percent at $52.60.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.